Aktis Oncology, Inc. (AKTS)

Aktis Oncology, Inc. (AKTS) is a healthcare company (biotechnology) based in the United States. The share price is $16.13, down 0.19% on the day, which values the company at $900.02M. Price as of 17 Nov 2026, 17:37 UTC, from Yahoo Finance.

Key facts

Share price
$16.13−0.19% today
Market value
$900.02M
Sector
Healthcare

Figures as of . Prices from Yahoo Finance (may be delayed); statements from company filings with the SEC and Yahoo Finance. Estimates, not advice.

Aktis Oncology, Inc. in more detail

AKTS trades at -7.1× next year's expected earnings, 72.7× sales.

Over the last five fiscal years Aktis Oncology, Inc. has compounded revenue 29.4% a year.

In its favour: More cash than debt. Worth checking: Altman Z in the distress zone; Weak Piotroski score.

2 of the superinvestors tracked here hold AKTS, including Peter Kolchinsky (0.4% of the portfolio), Julian and Felix Baker (0.2% of the portfolio).

Superinvestors holding AKTS

2 of the investors tracked here report a position in their latest 13F filing.

Aktis Oncology, Inc. (AKTS): questions and answers

What is Aktis Oncology, Inc.'s market cap?

Aktis Oncology, Inc. is valued at $900.02M at a share price of $16.13.

How fast is Aktis Oncology, Inc. growing?

Over the last five fiscal years Aktis Oncology, Inc.'s revenue grew 29.4% a year.

Does AKTS pay a dividend?

Aktis Oncology, Inc. does not currently pay a regular dividend.

Which famous investors own AKTS?

In their latest quarterly filings, Peter Kolchinsky (0.4% of the portfolio), Julian and Felix Baker (0.2% of the portfolio) hold AKTS. These filings are published up to 45 days after each quarter ends, so positions may have changed since.

Cite this page

Funkfolio, “Aktis Oncology, Inc. (AKTS) stock: price, valuation and fundamentals”, data as of 17 November 2026. https://funkfolio.com/stock/AKTS

Underlying data: Yahoo Finance; company filings with the SEC.